Tumor-associated antigen and neoantigen epitope (TAA/Neoantigen)

Tumor-associated antigens (TAAs) and neoantigens are peptides derived from cellular proteins that are presented on the surface of malignant cells by Major Histocompatibility Complex (MHC) molecules. TAAs include differentiation antigens, overexpressed proteins, and cancer-testis antigens that may be present in normal tissues at lower levels, while neoantigens arise from non-synonymous somatic mutations unique to the tumor genome (Nature Reviews Cancer, 2021). These epitopes serve as the primary targets for the adaptive immune system, where CD8+ T cells recognize MHC Class I-restricted peptides to exert direct cytotoxicity, and CD4+ T cells recognize MHC Class II-restricted peptides to provide essential cytokine support and orchestrate the broader immune response (NIH, 2023). In therapeutic development, these antigens are utilized in the design of cancer vaccines, TCR-engineered T-cell therapies, and personalized immunotherapies aimed at overcoming tumor-induced immunosuppression. The clinical success of targeting these epitopes depends heavily on the specificity of the antigen to minimize autoimmune damage to healthy tissues and the ability of the therapy to counter antigen loss or heterogeneity within the tumor microenvironment (PubMed, 2022).

Other names

Tumor-specific antigenTSACancer-testis antigenOncofetal antigenMutated self-antigenShared tumor antigenMHC-restricted peptide epitope

Induction of antigen-specific CD8+ and CD4+ T-cell responses through MHC-restricted recognition, leading to the targeted lysis of tumor cells and the establishment of immunological memory.